Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ge healthcare buchler gmbh & co. kg, nemecko - jodid sodný (131j) - 88 - radiopharmaca

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mundipharma gesellschaft m.b.h., rakúsko - hydromorfón - 65 - analgetica - anodyna

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mundipharma gesellschaft m.b.h., rakúsko - hydromorfón - 65 - analgetica - anodyna

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mundipharma gesellschaft m.b.h., rakúsko - hydromorfón - 65 - analgetica - anodyna

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mundipharma gesellschaft m.b.h., rakúsko - hydromorfón - 65 - analgetica - anodyna

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reckitt benckiser (czech republic), spol. s r.o. , Česká republika - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reckitt benckiser (czech republic), spol. s r.o. , Česká republika - ibuprofén - 07 - analgetica, antipyretica

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastické činidlá - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastické činidlá - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastické činidlá - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.